Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01900561 · ClinicalTrials.gov registry record · NA
Optimizing Veteran-Centered Prostate Cancer Survivorship Care
A NA study of Prostate Cancer, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- NA
- Development phase
- 556
- Enrollment target
- 4
- Study locations
NCT01900561: Completed NA study of Prostate Cancer, sponsored by VA Office of Research and Development.
NCT01900561 is a NA study of Prostate Cancer that has completed, run by VA Office of Research and Development. The registered enrollment target is 556 participants, roughly in line with the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target. The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01900561, a NA study of Prostate Cancer, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- NA
- Development phase
- 556 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study will provide much needed information about how to optimize the quality of care and quality of life of Veterans who are survivors of prostate cancer.
Primary Outcome
The EPIC is a 26-item measure that assesses symptom burden in four domains: urinary symptoms, bowel symptoms, sexual symptoms and vitality. Each domain has a subscale related to function and bother which together contribute to disease specific quality of life. Each domain has a range of possible scores from 0 to 100, with lower scores indicating worse symptom burden. Lower EPIC scores for any one domain are associated with lower function in that domain and lower QOL. Thus higher symptom burden,
Conditions Studied
Interventions
- BEHAVIORAL Interactive Voice Response Symptom Management
- BEHAVIORAL Tailored Newsletters
Study Locations (4)
Michigan
- VA Ann Arbor Healthcare System, Ann Arbor, MI - Ann Arbor
Missouri
- St. Louis VA Medical Center John Cochran Division, St. Louis, MO - St Louis
Ohio
- Louis Stokes VA Medical Center, Cleveland, OH - Cleveland
Pennsylvania
- VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 556 participants |
| Start Date | 2015-04-17 |
| Est. Completion | 2018-02-07 |
| Phase | NA |
What the finished NCT01900561 record still lists
NCT01900561 is an interventional study that assigns participants to a tested intervention. The registered 556 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Interactive Voice Response Symptom Management is the first listed.
NCT01900561 reports a single indexed study location in Michigan, Missouri, Ohio.
Frequently Asked Questions
What is clinical trial NCT01900561 about?
NCT01900561 is a clinical study titled "Optimizing Veteran-Centered Prostate Cancer Survivorship Care". This study will provide much needed information about how to optimize the quality of care and quality of life of Veterans who are survivors of prostate cancer.
What is the current status of trial NCT01900561?
This trial is currently completed. It is a NA study. The enrollment target is 556 participants. The study started on 2015-04-17. Estimated completion is 2018-02-07.
What conditions does trial NCT01900561 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT01900561?
The interventions under investigation include: Interactive Voice Response Symptom Management (BEHAVIORAL), Tailored Newsletters (BEHAVIORAL).
Who is sponsoring clinical trial NCT01900561?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01900561 being conducted?
This trial has 4 study locations across Michigan, Missouri, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01900561's enrollment target sits among peer trials
556 100th of 735 higher than 636 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
RECRUITING · NA
-
Diffusion Basis Spectrum Imaging of the Prostate
RECRUITING · NA
-
Micro-UltraSound In Cancer - Active Surveillance
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
SBRT Boost for Unfavorable Prostate Cancer'
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06074588 · 556 participants · Phase 3
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
- NCT06693622 · 556 participants
Patient Preferences for Barrett's Esophagus and Esophageal Cancer Screening Tests
- NCT05708885 · 557 participants · NA
Striated Esophageal Motor Function Modulation in Health and Disease
- NCT06799000 · 555 participants · Phase 3
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI